Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. CytoDyn Inc (CYDY) Message Board

Bingo, Tech Guru. Your post asks exactly the qu

Message Board Public Reply | Private Reply | Keep | Replies (1)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 154912
(Total Views: 783)
Posted On: 02/20/2022 8:17:28 AM
Posted By: KenChowder
Re: TechGuru #118753
Bingo, Tech Guru.

Your post asks exactly the questions we'd all like answers to -- and you could throw in one about the status of the Long Hauler trial, which was supposed to begin in January, and another one about the status of the HIV BLA applications, which was supposed to be completed in Q1 22, which ends in 39 days.

But your post also points out the absurd argument of those who basically shrug off the deafening silence since Jan. 13th as "bad results" or "no results."

For them to be right, the NASH 700mg trial would have to have worse results than the 350mg trial -- something which has never happened in any Leron trial.

And for them to be right, there would also have to be no further results from the mTNBC trial, even though the results 3 months ago still didn't include an EXACT mOS, because more than half the patients were still surviving at that time.

And for them to be right, there would also have be no further news from Brazil -- a mere 62 (I think it was) patients could not be enrolled yet, even though the pandemic worsened drastically there in early January and Albert Einstein has upped the number of participating hospitals to 32 (I think it was), and anyone with any sense would see that trial, with 4 doses beginning with an IV, as dead sure to have better results vs. Covid than any therapeutic ever tested.

And for them to be right, there would have to be no further movement in any direction of the LH trial protocol, and no chance that we might be closer in submitting the HIV BLA.

People who claim that there's no news because it's all bad news are basing their guess on a whole crew of unlikely propositions.

No, this is a silent period. Period.


(26)
(0)




CytoDyn Inc (CYDY) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us